Dubai: Julphar, a UAE-based global pharmaceutical company, have signed a five-year licensing agreement with MSD, a leading health care company. The agreement provides Julphar with exclusive rights to produce, market, distribute and sell certain MSD medicines in UAE, and other Gulf states.
The new partnership enhances patients’ access to cutting-edge therapies for diabetes, asthma, allergy, pain and inflammation.
“Our partnership with Julphar means stronger focus on innovative ways to address critical diseases, a closer connection with current and potential customers, and a region-wide focus on their health care needs. In light of the exemplary efforts by regional governments to improve their national healthcare systems,” said Ramsey Morad, vice-president, MSD for the Middle East region.
